Share

cover art for Effects of Race/Ethnicity on MS Diagnosis and Treatment

DKBmed Radio

Effects of Race/Ethnicity on MS Diagnosis and Treatment

How aware are clinicians that MS should no longer be considered a “White people only” disease? What roles have race and ethnicity been shown to play in MS disease severity and disability progression? What do health care professionals need to know to provide the most effective care for all their patients?

Join Dr. Yujie Wang from the University of Washington and Dr. Kimystian Harrison, a post doctoral fellow at Johns Hopkins University, as they explore these and other questions in this eMultipleSclerosis Review podcast.


Take our post-test to claim CME credits.

To read a companion newsletter click here.

More episodes

View all episodes

  • Clinical Management Considerations in Mild Asthma

    23:47
    Mild asthma. For patients showing wheezing and shortness of breath on moderate exertion, it’s one of the most common diagnoses, even when breath sounds are clear and pulmonary function testing is normal. What makes mild asthma “mild”? The key guidelines base the stage of a patient’s asthma on how difficult it is to treat. Does that mean the frequency of symptom occurrence? How often a rescue inhaler needs to be used? The frequency and severity of pulmonary exacerbations? How should mild asthma be treated? What are the risks and benefits of short-acting beta agonists versus long-acting beta agonists versus inhaled corticosteroids? Which combinations might be appropriate for which patients?Join us in this issue of ePulmonology Review, as Dr. Fawzy from the Johns Hopkins University School of Medicine’s Division of Pulmonary and Critical Care discusses these and other issues important to providing the best care for patients with mild asthma.Post test for CME/CE credit: https://elit.dkbmed.com/issues/197/test
  • PH in the Clinic: The Revised WHO Classifications

    25:30
    Pulmonary hypertension. The 2022 ESC/ERS revised guidelines have redefined it. New evidence from ongoing and completed clinical trials have led to updates in diagnostic thresholds and treatment algorithms. New agents — some approved, others advancing through the pipeline — promise improved efficacy and safety for a variety of patients. What does it all mean to practitioners in the clinic?Post test for CME/CE credit: https://elit.dkbmed.com/issues/195/test
  • Clinical Approaches to Marginalized Populations

    35:03
    In part 1 of this eHIV Review Special Edition (still available at eHIVreview.org), eHIV Review Program Director Justin Alves, Nurse Educator at Boston Medical Center, reviewed the recent evidence describing some of the barriers to care experienced by marginalized individuals at risk for or living with HIV. In this Part 2 issue, he again calls upon two front-line clinicians in the fight to end the HIV epidemic in the U.S. — Nicky Mehtani, MD, from UCSF Medical Center in San Francisco, and Vanessa Loukas, NP, from Boston University’s Chobanian & Avedisian School of Medicine —to share their clinical approaches.Post test for CME/CE credit: https://elit.dkbmed.com/issues/191/test
  • Addressing the Needs of Marginalized Populations - Mehtani

    04:43
    Marginalized individuals at risk for or living with HIV — the formerly incarcerated, immigrants, people with unstable housing, residents of rural communities, the rising number with substance use disorder — have long faced disparities in obtaining adequate health care. What do HCPs need to know to understand the unique needs of these underserved populations? How can they provide meaningful, helpful, and culturally sensitive care? What barriers continue to prevent their being brought into the HIV care continuum?
  • Addressing the Needs of Marginalized Populations - Loukas

    02:18
    Marginalized individuals at risk for or living with HIV — the formerly incarcerated, immigrants, people with unstable housing, residents of rural communities, the rising number with substance use disorder — have long faced disparities in obtaining adequate health care. What do HCPs need to know to understand the unique needs of these underserved populations? How can they provide meaningful, helpful, and culturally sensitive care? What barriers continue to prevent their being brought into the HIV care continuum?
  • HIV Stigma: A Psychologist’s Viewpoint

    30:59
    A wealth of evidence confirms that adolescents and young adults (AYA) are indeed a priority population whose needs must be addressed for the US Ending the HIV Epidemic program to be successful. What do providers need to know about AYA to bring more of these patients into the HIV care continuum? What should they be doing? And what should they avoid doing?Join us as guest author Dr. Vincent Guilamo-Ramos from the Duke University School of Nursing answers these and other questions, in this issue of eHIV Review.Post test for CME/CE credit: https://elit.dkbmed.com/issues/183/testCompanion newsletter: https://elit.dkbmed.com/issues/182
  • Using the New Biomarkers in Clinical Practice

    25:55
    NfL — neurofilament light, from the blood, not the CSF. Is it a reliable indicator of MS activity, a predictor of relapse-related disability, and a monitor of treatment efficacy? OCT — optical coherence tomography. Fast, safe, reliable, and repeatable, it can reveal the cellular layers inside the retina. But how well does what OCT shows correlate with outcomes of importance in MS? And most important, how can these new biomarkers help clinicians care for their patients with MS now? Join us, as guest author Dr. Emily Schorr from the Department of Neurosciences at the University of California San Diego, addresses some of these questions in this issue of eMultipleSclerosis Review.Post test for CME/CE credit: https://elit.dkbmed.com/issues/181/testCompanion newsletter: https://elit.dkbmed.com/issues/180
  • AYA and Ending the HIV Epidemic

    25:29
    A wealth of evidence confirms that adolescents and young adults (AYA) are indeed a priority population whose needs must be addressed for the US Ending the HIV Epidemic program to be successful. What do providers need to know about AYA to bring more of these patients into the HIV care continuum? What should they be doing? And what should they avoid doing?Join us as guest author Dr. Vincent Guilamo-Ramos from the Duke University School of Nursing answers these and other questions, in this issue of eHIV Review.Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/179/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/175)
  • Emerging MS Clinical Options

    24:18
    Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety?Join us, as guest host Dr. Cole Harrington from the Ohio State University explores these important topics in this issue of eMultipleSclerosis Review.Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/178/test)Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/176)